

Appendix: Tables

1.	Sales January to March 2023 and 2022	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2023 vs. YTD March 2022	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to March 2023 and 2022

CHF millions	Three months ended 31 March		% change	
	2023	2022	At CER	In CHF
Pharmaceuticals Division	11,699	11,159	9	5
United States	5,853	5,489	6	7
Europe	2,071	2,072	5	0
Japan	1,390	1,337	18	4
International*	2,385	2,261	13	5
Diagnostics Division	3,623	5,286	-28	-31
Roche Group	15,322	16,445	-3	-7

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022

CHF millions	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022
Pharmaceuticals Div.	11,159	6	11,188	0	10,842	-6	12,362	9	11,699	9
United States	5,489	2	5,874	1	5,836	-6	6,123	1	5,853	6
Europe	2,072	-1	2,032	-6	1,996	4	2,043	-3	2,071	5
Japan	1,337	69	865	3	827	-27	1,920	69	1,390	18
International*	2,261	0	2,417	4	2,183	-3	2,276	4	2,385	13
Diagnostics Division	5,286	24	4,662	0	3,900	-4	3,882	-9	3,623	-28
Roche Group	16,445	11	15,850	0	14,742	-6	16,244	4	15,322	-3

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2023 vs. YTD March 2022

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,636	14	1,188	13	298	11	-	-	150	32
Perjeta	1,049	11	392	8	220	1	53	2	384	22
Hemlibra	1,034	24	631	21	206	27	92	24	105	38
Tecentriq	920	15	507	14	195	11	105	12	113	34
Actemra/RoActemra	676	-12	296	-22	193	-8	77	-	110	10
Ronapreve	567	9	-	-	-	-	567	33	-	-
Kadcyla	509	5	198	-3	154	-6	26	-8	131	42
Xolair	479	5	479	5	-	-	-	-	-	-
Herceptin	477	-17	91	-37	97	-17	9	-30	280	-7
MabThera/Rituxan	459	-17	274	-21	51	-	6	-13	128	-12
Vabysmo	432	**	360	**	44	-	21	-	7	-
Avastin	416	-24	133	-25	30	-45	91	-21	162	-19
Alecensa	372	9	106	7	73	3	50	5	143	14
Evrysdi	363	62	124	13	113	74	21	47	105	189
Activase/TNKase	302	23	288	23	-	-	-	-	14	17
Phesgo	241	72	98	62	114	59	-	-	29	232
Gazyva	197	24	99	32	55	25	8	-35	35	27
Lucentis	167	-35	167	-35	-	-	-	-	-	-
Polivy	150	96	46	35	40	93	51	169	13	340
Pulmozyme	127	-5	83	-5	20	-16	-	-	24	10
Enspryng	54	42	15	16	4	96	33	44	2	246
Rozlytrek	19	21	10	0	4	80	2	5	3	144

Xofluza	18	**	1	-10	-	-	-	-	17	**
Lunsumio	14	-	12	-	2	-	-	-	-	-
Cotellic	12	-2	5	21	3	-17	-	-	4	-9
Gavreto	10	95	6	48	2	83	-	-	2	**
Luxturna	4	-23	4	-23	-	-	-	-	-	-
Susvimo	1	-33	1	-33	-	-	-	-	-	-
Pharma other	994	-15	239	-38	153	-20	178	4	424	2
Pharma total sales	11,699	9	5,853	6	2,071	5	1,390	18	2,385	13

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022
Ocrevus	1,449	18	1,461	17	1,517	16	1,609	18	1,636	14
Perjeta	993	1	1,068	9	1,029	5	997	4	1,049	11
Hemlibra	853	30	973	31	952	23	1,045	24	1,034	24
Tecentriq	825	8	933	13	934	9	1,025	24	920	15
Actemra/RoActemra	792	3	663	-23	584	-42	662	-22	676	-12
Ronapreve	587	272	22	-91	22	-92	1,048	118	567	9
Kadcyla	511	9	563	18	516	6	490	-3	509	5
Xolair	456	9	569	13	600	8	583	6	479	5
Herceptin	607	-19	572	-11	493	-23	470	-22	477	-17
MabThera/Rituxan	564	-21	553	-20	479	-19	479	-20	459	-17
Vabysmo	21	-	88	-	173	-	309	-	432	*
Avastin	581	-32	561	-27	510	-28	470	-25	416	-24
Alecensa	361	23	384	16	382	11	386	10	372	9
Evrysdi	226	189	274	65	293	93	326	59	363	62
Activase/TNKase	247	-20	312	1	322	-5	296	-27	302	23
Phesgo	146	410	179	168	201	76	214	73	241	72
Gazyva	165	7	184	9	190	9	191	9	197	24
Lucentis	256	-26	316	-9	228	-39	212	-40	167	-35
Polivy	81	89	96	93	113	63	147	97	150	96
Pulmozyme	136	-3	143	2	135	-3	129	-15	127	-5

* Over 500%

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022
Ocrevus	1,050	12	1,090	10	1,143	17	1,204	15	1,188	13
Perjeta	362	-1	378	4	395	0	398	13	392	8
Hemlibra	520	28	578	24	586	16	632	21	631	21
Tecentriq	446	10	505	15	500	3	524	20	507	14
Actemra/RoActemra	380	22	284	-31	250	-61	282	-42	296	-22
Ronapreve	-	-	-	-	-	-	-	-	-	-
Kadcyla	204	0	211	-1	204	-8	201	-4	198	-3
Xolair	456	9	569	13	600	8	583	6	479	5
Herceptin	144	-26	119	-29	113	-29	100	-29	91	-37
MabThera/Rituxan	347	-20	344	-24	311	-14	314	-15	274	-21
Vabysmo	21	-	80	-	152	-	264	-	360	*
Avastin	178	-39	164	-36	155	-31	137	-26	133	-25
Alecensa	99	25	108	14	124	22	122	13	106	7
Evrysdi	109	36	118	28	121	13	122	20	124	13
Activase/TNKase	234	-21	297	1	305	-6	278	-29	288	23
Phesgo	60	187	78	134	79	62	87	58	98	62
Gazyva	75	0	86	3	90	7	94	11	99	32
Lucentis	256	-26	316	-9	228	-39	212	-40	167	-35
Polivy	34	75	43	97	44	57	44	65	46	35
Pulmozyme	87	0	97	5	96	2	89	-17	83	-5

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022
Ocrevus	280	34	259	34	269	11	267	26	298	11
Perjeta	228	-21	229	-12	204	-15	210	-15	220	1
Hemlibra	170	31	190	29	182	36	199	27	206	27
Tecentriq	183	14	200	24	190	17	221	23	195	11
Actemra/RoActemra	220	-4	200	-2	182	-3	200	-14	193	-8
Ronapreve	62	-61	3	-99	37	-54	-1	-100	-	-
Kadcyla	172	8	178	12	158	3	163	-2	154	-6
Xolair	-	-	-	-	-	-	-	-	-	-
Herceptin	122	-13	111	-9	96	-18	93	-27	97	-17
MabThera/Rituxan	54	-19	51	-16	51	-18	48	-21	51	0
Vabysmo	-	-	-	-	4	-	18	-	44	-
Avastin	58	-56	58	-49	42	-47	35	-56	30	-45
Alecensa	75	5	74	8	69	5	74	3	73	3
Evrysdi	68	*	84	227	101	216	100	116	113	74
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Phesgo	76	*	87	188	100	107	104	61	114	59
Gazyva	46	-5	49	-8	49	-9	48	-8	55	25
Lucentis	-	-	-	-	-	-	-	-	-	-
Polivy	22	4	24	30	38	88	48	144	40	93
Pulmozyme	26	-11	25	-12	22	-12	23	-13	20	-16

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	59	-1	61	-1	55	-1	59	3	53	2
Hemlibra	84	15	96	24	97	22	100	14	92	24
Tecentriq	107	-5	111	-9	108	0	117	6	105	12
Actemra/RoActemra	87	12	87	-2	82	-4	86	6	77	0
Ronapreve	483	-	-16**	-	-15**	-100	1,028	313	567	33
Kadcyla	32	28	36	20	33	16	30	2	26	-8
Xolair	-	-	-	-	-	-	-	-	-	-
Herceptin	15	-30	13	-27	12	-28	11	-28	9	-30
MabThera/Rituxan	8	-15	9	-2	7	-13	8	-23	6	-13
Vabysmo	-	-	7	-	17	-	23	-	21	-
Avastin	131	-12	132	-13	115	-19	112	-21	91	-21
Alecensa	54	7	60	5	55	4	59	7	50	5
Evrysdi	17	-	21	-	22	*	24	83	21	47
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Phesgo	-	-	-	-	-	-	-	-	-	-
Gazyva	15	8	13	-10	11	-17	11	-12	8	-35
Lucentis	-	-	-	-	-	-	-	-	-	-
Polivy	21	-	22	226	25	34	45	92	51	169
Pulmozyme	-	-	-	-	-	-	1	38	-	-

* Over 500%

**Effect of currency revaluation (CHF/JPY) on CHF483mn Q1 2022 Ronapreve sales

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022
Ocrevus	119	29	112	62	105	26	138	29	150	32
Perjeta	344	32	400	37	375	30	330	13	384	22
Hemlibra	79	63	109	115	87	53	114	45	105	38
Tecentriq	89	0	117	17	136	30	163	70	113	34
Actemra/RoActemra	105	-30	92	-44	70	-44	94	51	110	10
Ronapreve	42	-	35	-68	-	-	21	-81	-	-
Kadcyla	103	26	138	81	121	46	96	-3	131	42
Xolair	-	-	-	-	-	-	-	-	-	-
Herceptin	326	-18	329	-3	272	-22	266	-17	280	-7
MabThera/Rituxan	155	-23	149	-13	110	-32	109	-28	128	-12
Vabysmo	-	-	1	-	-	-	4	-	7	-
Avastin	214	-23	207	-17	198	-23	186	-16	162	-19
Alecensa	133	45	142	29	134	9	131	13	143	14
Evrysdi	32	**	51	-5	49	231	80	73	105	189
Activase/TNKase	13	-3	15	4	17	12	18	20	14	17
Phesgo	10	**	14	278	22	20	23	**	29	232
Gazyva	29	75	36	101	40	91	38	62	35	27
Lucentis	-	-	-	-	-	-	-	-	-	-
Polivy	4	40	7	145	6	135	10	86	13	340
Pulmozyme	23	-4	21	14	17	-16	16	-9	24	10

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%